BUY WOCKHARDT

Traded @ BSE/NSE (532300)Target : 1000+ Wockhardt is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India?s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 8600 Wockhardt Associates from 21 different nationalities globally. It has 3 research centres and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. Wockhardt is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process and techno-innovation within Wockhardt. At Wockhardt, we are looking at new ways of thinking, new ways of working and new ways to touch people?s lives. Wockhardt?s core business is innovation. It uses science and technology to develop medicines and other products that improve the quality of millions people?s lives through better health. Wockhardt has proved its technical excellence by developing patented modified release formulations and recombinant biotechnology products. It has a multi-disciplinary R&D programme with more than 607 scientists, including over 80 doctorates, in the areas of: Pharmaceutical Research,Biotechnology & Genomics Research,Novel Drug Delivery Systems New Drug Discovery Programme. API Research Wockhardt aspires to create a healthier world. Its strategic vision of ?More & More with Less & Less? has transformed into new ways of thinking, a new journey for growth, medical breakthroughs for patients and continuing value for all stakeholders. Wockhardt works with partners to in-license products in India and out-license products into other regions by capitalising on these collaborative strengths to capture and penetrate new markets. Wockhardt has vast international expertise in the manufacture of pharmaceuticals and biopharmaceutical formulations as well as Active Pharmaceutical Ingredients (API). The company has successfully created an integrated multi-technology capability to manufacture all types of dosage forms including sterile injectables and lyophilised products. Highly skilled technicians operate 12 manufacturing facilities that are US FDA, UK MHRA and EMEA compliant sites in India, the US and Europe. The state-of-the-art biotech plant in Aurangabad has six dedicated manufacturing facilities for biopharmaceutical bulk as well as recombinant formulations. The Wockhardt Biotech Park has created its own benchmark in manufacturing recombinant products with world-class technology. US FDA : Fast Track Approval for WOCKHARDT Drugs............... That's Means.... ACHE Din for Wockhardt AANE WALA HAI................!! It May Open 3 to 5% Up.... Don't Worry & Grab................. Oh Yes... EXACT Opening Price Buy @ 710 - 715 Today's Target : 735 - 750+ Ultimate Target : 1000+ SL : 660 U : Enjoy : We're Working for You...

Traded @ BSE/NSE (532234)Target : 70+ Buy @ 57 - 57.50 Today's Target : 63 - 65+ Ultimate Target  : 70+ SL :52

Traded @ BSE/NSE (532756)Target : 220+ Buy @ 177 - 178 Today's Target : 195 - 200+ Ultimate Target  : 220+ SL :160